Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sihuan Pharma Starts China Phase II Lung Cancer Trial

publication date: Aug 14, 2018

Sihuan Pharma has started a China Phase II Trial of pirotinib, a novel EGFR treatment for cancer, in patients with non-small cell lung cancer (NSCLC). The company conducted the earlier Phase I trial in the US. Sihuan, which claims to be the largest cardio-cerebral vascular drug maker in China, developed the candidate through its own R&D efforts. Sihuan was the first China biopharma to privatize from an ex-China exchange and then re-list in China, raising $741 million in a 2010 Hong Kong IPO. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.